DR-220 An exploratory study on genomic correlates of anti-tumour immunity in castration-resistant prostate cancer.
Checkpoint inhibitors have failed to demonstrate a survival benefit in unselected castration-resistant prostate cancer (CRPC) patients. Nevertheless, biochemical and radiographic responses have been observed in a subset of trial participants. Here, we will study the association between immune signatures, genomic aberrations and clinical outcome to identify more immunogenic subgroups. A better understanding of factors that influence the immune infiltrate can help to select subgroups for checkpoint inhibitors and might serve as starting point for other immune-based therapies in prostate cancer.
Niven Mehra Radboudumc the Netherlands
Terug naar nieuwsMeer nieuws
Nederland opent databank met DNA van kankerpatiënten
De behandeling voor kankerpatiënten is nog onvoldoende afgestemd op de specifieke kenmerken van de tumoren. Om patronen te kunnen ontdekken …
Medicalfacts: onderzoek naar optimale inzet van genetische testen voor “Immunotherapie” bij kanker
Momenteel komen er in toenemende mate nieuwe, vaak dure, medicijnen tegen kanker op de markt. Behandelingen die nu worden gegeven …
Measuring the effects of radiotherapy on cancer may open up avenues for treatment
Radiotherapy works by damaging the DNA of cancer cells. It’s an effective strategy overall, but many cancers have subsets of …
Unieke dataset Hartwig heeft onze visie op uitgezaaide kanker verrijkt.